“Elritercept has the potential to make a meaningful difference for patients with blood cancers, one of our key areas of strategic focus,” said Teresa Bitetti, President of the Global Oncology Business Unit at Takeda. “The addition of elritercept further bo...
We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are ...
TORONTO, Ontario – May 9, 2023– Takeda Canada Inc. (“Takeda”) announces results from the EVOLVE Expansion study, which evaluated the safety and efficacy of vedolizumab (ENTYVIO®), a gut-selective α4...
“Adding this TYK2 inhibitor to our late-stage pipeline gives Takeda an exciting program that has the potential to significantly expand our portfolio and patient impact, while enhancing our growth strategy beyond ENTYVIO®” said Christophe Weber, president and chief executive officer of Takeda. “W...
Our team brings an outstanding track record and a wealth of knowledge in global vaccine development and manufacturing to advance a pipeline of vaccines to help address some of the most pressing public health needs. Our mission is to develop and deliver innovative vaccines that tackle some of the...
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Acro...
Attributing losses to exchange rate and pipeline impairment losses, the Japanese biopharma dropped its reported net profit forecast of 142 billion yen ($945.1 million) to 93 billion yen ($618.8 million).
Takeda Pharmaceutical: Strong Financials, Strategic Leadership Change, and Robust Pipeline Justify Buy Rating Jan. 31, 2025 at 6:46 a.m. ET on TipRanks.com Takeda Pharmaceutical Co.: Hold Rating Amid Mixed Q3 Results, Upward Guidance Revision, and Strategic Moves Jan. 31, 2025 at 2:16...
Takeda Pharmaceutical: Strong Financials, Strategic Leadership Change, and Robust Pipeline Justify Buy Rating Jan. 31, 2025 at 6:46 a.m. ET on TipRanks.com Takeda Pharmaceutical Co.: Hold Rating Amid Mixed Q3 Results, Upward Guidance Revision, and Strategic Moves Jan. 31, 2025 at 2:16...
20 Jun 2023Phase-I clinical trials in Non-alcoholic steatohepatitis (SC) (Takeda pipeline, June 2023) You need to be a logged in or subscribed to view this contentRequest demo If your organization or you do not have a subscription, try one of the following: ...